Kliniske studier for Lupus i Tennessee
13 studier for Lupus søker deltakere på steder i Tennessee.
Byer i Tennessee
Offisiell studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50001, Jackson
- Sl0044 50693, Murfreesboro
RekruttererFase 3
Alder 16 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06617325A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- West Tennessee Research Institute, Jackson
- Shelby Research LLC, Memphis
RekruttererFase 2
Alder 18 til 74 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07409181Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- West Tennessee Research Institute, Jackson
- Shelby Research LLC, Memphis
RekruttererFase 3
Alder 12 til 100 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06133972A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Memphis
- Research Site, Memphis
RekruttererFase 3
Alder 18 til 70 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07430306A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- West Tennessee Research Institute, Jackson
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- West Tennessee Research Institute - Jackson /ID# 284561, Jackson
RekruttererFase 1
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07607964A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Murfreesboro Medical Clinic, Murfreesboro
RekruttererObservasjonsstudie
Alder 16 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07175285A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Private Practice - Dr. Ramesh C. Gupta /ID# 275826, Memphis
RekruttererFase 1
Alder 18 til 75 · Alle kjønn · Oppdatert 10. aug. 2026 · NCT06977724A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
- Investigative Site, Memphis
RekruttererFase 2
Alder 18 til 80 · Alle kjønn · Oppdatert 27. jul. 2026 · NCT07260877A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- Regional One Health, Memphis
RekruttererFase 1
Alder 18 til 70 · Alle kjønn · Oppdatert 5. jun. 2026 · NCT066133602-HOBA in Systemic Lupus Erythematosus
- Vanderbilt University Medical Center, Nashville
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 22. mai 2026 · NCT07225543A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Regional One Health, Memphis
RekruttererFase 1
Alder 12 til 70 · Alle kjønn · Oppdatert 22. mai 2026 · NCT06308978Lupus Landmark Study: A Prospective Registry and Biorepository
- Vanderbilt University Medical Center, Nashville
RekruttererObservasjonsstudie
Alder 18 til 110 · Alle kjønn · Oppdatert 15. apr. 2026 · NCT05934149Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.